Skip Navigation

European Journal of Heart Failure 2001 3(6):747-750; doi:10.1016/S1388-9842(01)00210-0
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coletta, A. P.
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coletta, A. P.
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology — WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME

Alison P. Coletta and John G.F. Cleland*

Department of Academic Cardiology, Castle Hill Hospital Cottingham, Kingston upon Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44-1482-624084; fax: +44-1482-624085. E-mail address: j.g.cleland{at}hull.ac.uk (J.G. Cleland).


  Abstract

This article continues a series of reports updating recent research developments of particular interest to personnel involved in the treatment and management of patients with heart failure. This is a summary of selected presentations made at the Scientific Sessions of the XXIII Annual Congress of the European Society of Cardiology. Summaries of the following clinical studies are included: WARIS-II, ESCAMI, PAFAC, RITZ-I and TIME.

Key Words: Heart failure • Cardiology • WARIS II • ESCAMI • PAFAC • RITZ-I • TIME

Received October 7, 2001; Revised October 12, 2001; Accepted October 15, 2001


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
A. Mebazaa, P. S. Pang, M. Tavares, S. P. Collins, A. B. Storrow, S. Laribi, S. Andre, D. M. Courtney, J. Hasa, J. Spinar, et al.
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study
Eur. Heart J., November 11, 2009; (2009) ehp458v1.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. S. Pang, M. A. Konstam, H. B. Krasa, K. Swedberg, F. Zannad, J. E.A. Blair, C. Zimmer, J. R. Teerlink, A. P. Maggioni, J. C. Burnett Jr, et al.
Effects of tolvaptan on dyspnoea relief from the EVEREST trials
Eur. Heart J., September 2, 2009; 30(18): 2233 - 2240.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P. S. Pang, J. G.F. Cleland, J. R. Teerlink, S. P. Collins, C. J. Lindsell, G. Sopko, W. F. Peacock, G. C. Fonarow, A. Z. Aldeen, J. D. Kirk, et al.
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
Eur. Heart J., March 2, 2008; 29(6): 816 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug.
Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S K Prasad, H J Dargie, G C Smith, M M Barlow, F Grothues, B A Groenning, J G F Cleland, and D J Pennell
Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study
Heart, June 1, 2006; 92(6): 798 - 803.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. M Tovar and J. G Gums
Tezosentan in the Treatment of Acute Heart Failure
Ann. Pharmacother., December 1, 2003; 37(12): 1877 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Rich and V. V. McLaughlin
Endothelin Receptor Blockers in Cardiovascular Disease
Circulation, November 4, 2003; 108(18): 2184 - 2190.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. P. Coletta, A. L. Clark, A.-M. L. Seymour, and J. G.F. Cleland
Clinical trials update from the European Society of Cardiology Heart Failure meeting: COMET, COMPANION, Tezosentan and SHAPE
Eur J Heart Fail, August 1, 2003; 5(4): 545 - 548.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. M. O'Connor, W. A. Gattis, K. F. Adams Jr, V. Hasselblad, B. Chandler, A. Frey, I. Kobrin, M. Rainisio, M. R. Shah, J. Teerlink, et al.
Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4)
J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1452 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A.P. Coletta, A.A. Louis, A.L. Clark, N. Nikitin, and J.G.F. Cleland
Clinical trials update from the European Society of Cardiology: CARMEN, EARTH, OPTIMAAL, ACE, TEN-HMS, MAGIC, SOLVD-X and PATH-CHF II
Eur J Heart Fail, October 1, 2002; 4(5): 661 - 666.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.